Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 658 of the 659 references it cites were found in a registry or an index.

Designer drugs: mechanism of action and adverse effects

Open access
Luethi, Dino, Liechti, Matthias E. · 2020 · Archives of Toxicology

Abstract

Psychoactive substances with chemical structures or pharmacological profiles that are similar to traditional drugs of abuse continue to emerge on the recreational drug market. Internet vendors may at least temporarily sell these so-called designer drugs without adhering to legal statutes or facing legal consequences. Overall, the mechanism of action and adverse effects of designer drugs are similar to traditional drugs of abuse. Stimulants, such as amphetamines and cathinones, primarily interact with monoamine transporters and mostly induce sympathomimetic adverse effects. Agonism at μ-opioid receptors and γ-aminobutyric acid-A (GABA A ) or GABA B receptors mediates the pharmacological effects of sedatives, which may induce cardiorespiratory depression. Dissociative designer drugs primarily act as N -methyl- d -aspartate receptor antagonists and pose similar health risks as the medically approved dissociative anesthetic ketamine. The cannabinoid type 1 (CB 1 ) receptor is thought to drive the psychoactive effects of synthetic cannabinoids, which are associated with a less desirable effect profile and more severe adverse effects compared with cannabis. Serotonergic 5-hydroxytryptamine-2A (5-HT 2A ) receptors mediate alterations of perception and cognition that are induced by serotonergic psychedelics. Because of their novelty, designer drugs may remain undetected by routine drug screening, thus hampering evaluations of adverse effects. Intoxication reports suggest that several designer drugs are used concurrently, posing a high risk for severe adverse effects and even death.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00204-020-02693-7

Cites

658 of 658 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 DAT vs. SERT selectivity of a variety of stimulants. Stimulants with low (< 0.1) DAT/SERT ratios are likely to induce entactogenic MDMA-like effects, while substances with a high (> 10) DAT/SERT ratio are associated with distinct psychostimulant effects and a high abuse potential. The DAT/SERT ratio is expressed as 1/DAT IC50: 1/SERT IC50. Full names of the substances and source of pharmacological data are provided in the supplementary information
Fig. 1 DAT vs. SERT selectivity of a variety of stimulants. Stimulants with low (< 0.1) DAT/SERT ratios are likely to induce entactogenic MDMA-like effects, while substances with a high (> 10) DAT/SERT ratio are associated with distinct psychostimulant effects and a high abuse potential. The DAT/SERT ratio is expressed as 1/DAT IC50: 1/SERT IC50. Full names of the substances and source of pharmacological data are provided in the supplementary informationCC BY · PubMed Central
Fig. 2 Correlation between reported clinical potencies and in vitro monoamine transporter inhibition of a variety of stimulants. Figure modified from (Luethi and Liechti 2018). Full names of the substances and source of pharmacological data are provided in the supplementary information
Fig. 2 Correlation between reported clinical potencies and in vitro monoamine transporter inhibition of a variety of stimulants. Figure modified from (Luethi and Liechti 2018). Full names of the substances and source of pharmacological data are provided in the supplementary informationCC BY · PubMed Central
Fig. 3 Examples of amphetamine, cathinone, and pyrovalerone derivatives. Full names of the substances are provided in the supplementary information
Fig. 3 Examples of amphetamine, cathinone, and pyrovalerone derivatives. Full names of the substances are provided in the supplementary informationCC BY · PubMed Central
Fig. 4 Examples of stimulant designer drugs and reference substances. Full names of the substances are provided in the supplementary information
Fig. 4 Examples of stimulant designer drugs and reference substances. Full names of the substances are provided in the supplementary informationCC BY · PubMed Central
Fig. 5 Examples of sedative designer drugs and reference substances for comparison. Full names of the substances are provided in the supplementary information
Fig. 5 Examples of sedative designer drugs and reference substances for comparison. Full names of the substances are provided in the supplementary informationCC BY · PubMed Central
Fig. 6 Examples of dissociative designer drugs and reference substances for comparison. Full names of the substances are provided in the supplementary information
Fig. 6 Examples of dissociative designer drugs and reference substances for comparison. Full names of the substances are provided in the supplementary informationCC BY · PubMed Central
Fig. 7 Structures of Δ9-THC and a selection of cannabinoid designer drugs. Full names of the substances are provided in the supplementary information
Fig. 7 Structures of Δ9-THC and a selection of cannabinoid designer drugs. Full names of the substances are provided in the supplementary informationCC BY · PubMed Central
Fig. 8 Correlation between reported clinical potencies and in vitro human 5-HT2A receptor affinities of a variety of psychedelics. Figure modified from (Luethi and Liechti 2018). Full names of the substances and source of pharmacological data are provided in the supplementary information
Fig. 8 Correlation between reported clinical potencies and in vitro human 5-HT2A receptor affinities of a variety of psychedelics. Figure modified from (Luethi and Liechti 2018). Full names of the substances and source of pharmacological data are provided in the supplementary informationCC BY · PubMed Central
Fig. 9 Examples of psychedelic phenethylamines, tryptamines, and lysergamides. Full names of the substances are provided in the supplementary information
Fig. 9 Examples of psychedelic phenethylamines, tryptamines, and lysergamides. Full names of the substances are provided in the supplementary informationCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 659 references

Research works printed but not linked: 5

  1. Heim R (2004) Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts. Dissertation, Freie Universität Berlin. https://refubium.fu-berlin.de/bitstream/handle/fub188/11995/0_RalfHeimTitelblatt.pdf?sequence=1&isAllowed=y. Accessed 7 Jan 2020
  2. Sanchez S (1929) Sur un homologue de l’éphédrine. Bull Soc Chim Fr 45:284–286
  3. Thorlacius K, Borna C, Personne M (2008) Bromo-dragonfly–livsfarlig missbruksdrog. Kan ge vävnadsnekros, visar det första beskrivna fallet. Lakartidningen 105(16):1199–200
  4. Topeff J, Ellsworth H, Willhite L, Bangh S, Edwards E, Cole J (2011) A case series of symptomatic patients, including one fatality, following 2C-E exposure. Clin Toxicol (Phila) 49:526
  5. Trachsel D, Lehmann D, Enzensperger C (2013) Phenethylamine: von der Struktur zur Funktion. Nachtschatten Verlag, Solothurn

Cited by

See all 262

Metadata

Authors
Luethi, D., & Liechti, M. E.
Affiliations
  • TU Wien (AT)
  • University of Basel (CH)
Corresponding author
Luethi, Dino
Venue
Archives of Toxicology
Published
2020-04
Volume
94
Issue
4
Pages
1085-1133
ISSN
  • 0340-5761 (ISSN-L)
  • 1432-0738
OpenAlex
W3014121938
Cited by
262
References
659
Citations by year
2026: 29 · 2025: 43 · 2024: 43 · 2023: 42 · 2022: 55 · 2021: 35 · 2020: 13
FWCI
7.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Archives of Toxicology (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • edoc (University of Basel) (submittedVersion)
Funders
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2BSP3_181809)
  • Bundesamt für Gesundheit (16.921318)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
  • Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
new psychoactive substances, mechanism of action, adverse drug reactions, stimulants, cathinone, monoamine transporters, sympathomimetic effects, sedatives, mu-opioid receptor agonism, GABA receptors, cardiorespiratory depression, dissociative drugs, NMDA receptor antagonists, ketamine, synthetic cannabinoids, CB1 receptor, serotonergic psychedelics, 5-HT2A receptor, drug screening, polydrug use
MeSH terms
Central Nervous System Stimulants, Cannabinoids, Hallucinogens, Humans, Psychotropic Drugs, Serotonin, Illicit Drugs, Designer Drugs, Molecular Structure, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Designer drugs: mechanism of action and adverse effects. https://app.cochat.ai/papers/10.1007/s00204-020-02693-7
The paper
Luethi, D., & Liechti, M. E. (2020). Designer drugs: mechanism of action and adverse effects. Archives of Toxicology. https://doi.org/10.1007/s00204-020-02693-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.